Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Tumors Metastatic to the CNS
NCT04992013Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in central nervous system cancer, metastatic cancer, sponsored by Massachusetts General Hospital. Started Apr 2022; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
central nervous system cancermetastatic cancer
Beyond the preview
Go deeper on NCT04992013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992013.